173 PsA pts enrolled to start ustekinumab: half on MTX and half on PBO. At week 24 there was no difference in DAS28 between groups (2.9 vs 3.1); then Ustekinumab plus placebo was non-inferior to ustekinumab plus methotrexate https://t.co/AygtawIZsZ https://t.co/YLGp5lMWT9